155 related articles for article (PubMed ID: 37958302)
1. Impact of Waiting Response Evaluation to First-Line Systemic Therapy before Considering Local Ablative Therapy in Metastatic Non-Small-Cell Lung Cancer.
Belaidi L; Wang P; Quintin K; Durdux C; Giroux-Leprieur E; Giraud P
Cancers (Basel); 2023 Oct; 15(21):. PubMed ID: 37958302
[TBL] [Abstract][Full Text] [Related]
2. Stereotactic radiotherapy combined with immunotherapy or targeted therapy for metastatic renal cell carcinoma.
Kroeze SGC; Fritz C; Schaule J; Siva S; Kahl KH; Sundahl N; Blanck O; Kaul D; Adebahr S; Verhoeff JJC; Skazikis G; Roeder F; Geier M; Eckert F; Guckenberger M
BJU Int; 2021 Jun; 127(6):703-711. PubMed ID: 33113260
[TBL] [Abstract][Full Text] [Related]
3. Radiosurgery and fractionated stereotactic radiotherapy in oligometastatic/oligoprogressive non-small cell lung cancer patients: Results of a multi-institutional series of 198 patients treated with "curative" intent.
Buglione M; Jereczek-Fossa BA; Bonù ML; Franceschini D; Fodor A; Zanetti IB; Gerardi MA; Borghetti P; Tomasini D; Di Muzio NG; Oneta O; Scorsetti M; Franzese C; Romanelli P; Catalano G; Dell'Oca I; Beltramo G; Ivaldi GB; Laudati A; Magrini SM; Antognoni P;
Lung Cancer; 2020 Mar; 141():1-8. PubMed ID: 31926440
[TBL] [Abstract][Full Text] [Related]
4. Stereotactic Radiotherapy for Oligoprogression in Metastatic Renal Cell Cancer Patients Receiving Tyrosine Kinase Inhibitor Therapy: A Phase 2 Prospective Multicenter Study.
Cheung P; Patel S; North SA; Sahgal A; Chu W; Soliman H; Ahmad B; Winquist E; Niazi T; Patenaude F; Lim G; Heng DYC; Dubey A; Czaykowski P; Wong RKS; Swaminath A; Morgan SC; Mangat R; Keshavarzi S; Bjarnason GA
Eur Urol; 2021 Dec; 80(6):693-700. PubMed ID: 34399998
[TBL] [Abstract][Full Text] [Related]
5. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.
Chen L; Douglass J; Kleinberg L; Ye X; Marciscano AE; Forde PM; Brahmer J; Lipson E; Sharfman W; Hammers H; Naidoo J; Bettegowda C; Lim M; Redmond KJ
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):916-925. PubMed ID: 29485071
[TBL] [Abstract][Full Text] [Related]
6. Stereotactic radiation therapy in the strategy of treatment of metastatic renal cell carcinoma: A study of the Getug group.
Meyer E; Pasquier D; Bernadou G; Calais G; Maroun P; Bossi A; Theodore C; Albiges L; Stefan D; de Crevoisier R; Hennequin C; Lagrange JL; Grellard JM; Clarisse B; Licaj I; Habrand JL; Carrie C; Joly F
Eur J Cancer; 2018 Jul; 98():38-47. PubMed ID: 29864737
[TBL] [Abstract][Full Text] [Related]
7. Immune checkpoint inhibition in patients treated with stereotactic radiation for brain metastases.
Kowalski ES; Remick JS; Sun K; Alexander GS; Khairnar R; Morse E; Cherng HR; Berg LJ; Poirier Y; Lamichhane N; Becker S; Chen S; Molitoris JK; Kwok Y; Regine WF; Mishra MV
Radiat Oncol; 2020 Oct; 15(1):245. PubMed ID: 33109224
[TBL] [Abstract][Full Text] [Related]
8. Checkpoint Inhibitors in Combination With Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors: The CHEERS Phase 2 Randomized Clinical Trial.
Spaas M; Sundahl N; Kruse V; Rottey S; De Maeseneer D; Duprez F; Lievens Y; Surmont V; Brochez L; Reynders D; Danckaert W; Goetghebeur E; Van den Begin R; Van Gestel D; Renard V; Dirix P; Ost P
JAMA Oncol; 2023 Sep; 9(9):1205-1213. PubMed ID: 37410476
[TBL] [Abstract][Full Text] [Related]
9.
Bahig H; Tonneau M; Blais N; Wong P; Filion E; Campeau MP; Vu T; Al-Saleh A; Tehfé M; Florescu M; Roberge D; Masucci L; Richard C; Menard C; Routy B
Clin Transl Radiat Oncol; 2022 Mar; 33():115-119. PubMed ID: 35243022
[TBL] [Abstract][Full Text] [Related]
10. Overall survival according to immunotherapy and radiation treatment for metastatic non-small-cell lung cancer: a National Cancer Database analysis.
Foster CC; Sher DJ; Rusthoven CG; Verma V; Spiotto MT; Weichselbaum RR; Koshy M
Radiat Oncol; 2019 Jan; 14(1):18. PubMed ID: 30691492
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of immune checkpoint inhibitors with or without radiotherapy in metastatic non-small cell lung cancer: A systematic review and meta-analysis.
Liu Z; Xu T; Chang P; Fu W; Wei J; Xia C; Wang Q; Li M; Pu X; Huang F; Ge C; Gao Y; Gong S; Liu C; Dong L
Front Pharmacol; 2023; 14():1064227. PubMed ID: 36762107
[No Abstract] [Full Text] [Related]
12. Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer.
Mezquita L; Auclin E; Ferrara R; Charrier M; Remon J; Planchard D; Ponce S; Ares LP; Leroy L; Audigier-Valette C; Felip E; Zerón-Medina J; Garrido P; Brosseau S; Zalcman G; Mazieres J; Caramela C; Lahmar J; Adam J; Chaput N; Soria JC; Besse B
JAMA Oncol; 2018 Mar; 4(3):351-357. PubMed ID: 29327044
[TBL] [Abstract][Full Text] [Related]
13. Metastasis directed stereotactic radiotherapy in NSCLC patients progressing under targeted- or immunotherapy: efficacy and safety reporting from the 'TOaSTT' database.
Kroeze SGC; Schaule J; Fritz C; Kaul D; Blanck O; Kahl KH; Roeder F; Siva S; Verhoeff JJC; Adebahr S; Schymalla MM; Glatzer M; Szuecs M; Geier M; Skazikis G; Sackerer I; Lohaus F; Eckert F; Guckenberger M
Radiat Oncol; 2021 Jan; 16(1):4. PubMed ID: 33407611
[TBL] [Abstract][Full Text] [Related]
14. Adverse impact of bone metastases on clinical outcomes of patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors.
Li X; Wang L; Chen S; Zhou F; Zhao J; Zhao W; Su C
Thorac Cancer; 2020 Oct; 11(10):2812-2819. PubMed ID: 32779372
[TBL] [Abstract][Full Text] [Related]
15. Stereotactic radiation therapy for oligometastatic esophagogastric adenocarcinoma: outcome and prognostic factors.
Franceschini D; Teriaca MA; Di Cristina L; Vernier V; Lo Faro L; Franzese C; Comito T; Clerici E; Bellu L; Dominici L; Spoto R; Massaro M; Navarria P; Scorsetti M
Br J Radiol; 2023 Mar; 96(1144):20220771. PubMed ID: 36809197
[TBL] [Abstract][Full Text] [Related]
16. Oligometastatic non-small cell lung cancer: a narrative review of stereotactic ablative radiotherapy.
Dohopolski M; Iyengar P
Ann Palliat Med; 2021 May; 10(5):5944-5953. PubMed ID: 33691460
[TBL] [Abstract][Full Text] [Related]
17. Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial.
Iyengar P; Wardak Z; Gerber DE; Tumati V; Ahn C; Hughes RS; Dowell JE; Cheedella N; Nedzi L; Westover KD; Pulipparacharuvil S; Choy H; Timmerman RD
JAMA Oncol; 2018 Jan; 4(1):e173501. PubMed ID: 28973074
[TBL] [Abstract][Full Text] [Related]
18. Benefit of ablative versus palliative-only radiotherapy in combination with nivolumab in patients affected by metastatic kidney and lung cancer.
Desideri I; Francolini G; Scotti V; Pezzulla D; Becherini C; Terziani F; Delli Paoli C; Olmetto E; Visani L; Meattini I; Greto D; Bonomo P; Loi M; Detti B; Livi L
Clin Transl Oncol; 2019 Jul; 21(7):933-938. PubMed ID: 30565084
[TBL] [Abstract][Full Text] [Related]
19. Combined Immunotherapy and Stereotactic Radiotherapy Improves Neurologic Outcomes in Patients with Non-small-cell Lung Cancer Brain Metastases.
Enright TL; Witt JS; Burr AR; Yadav P; Leal T; Baschnagel AM
Clin Lung Cancer; 2021 Mar; 22(2):110-119. PubMed ID: 33281062
[TBL] [Abstract][Full Text] [Related]
20. Development and validation of a host-dependent, PDL1-independent, biomarker to predict 6-month progression-free survival in metastatic non-small cell lung cancer (mNSCLC) patients treated with anti-PD1 immune checkpoint inhibitors (ICI) in the CERTIM Cohort: The ELY study.
Boudou-Rouquette P; Arrondeau J; Gervais C; Durand JP; Fabre E; De Percin S; Villeminey CV; Piketty AC; Rassy N; Ulmann G; Damotte D; Mansuet-Lupo A; Giraud F; Alifano M; Wislez M; Alexandre J; Jouinot A; Goldwasser F
EBioMedicine; 2021 Nov; 73():103630. PubMed ID: 34688030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
